This study is looking into how well and how safely a drug called prasinezumab works for people with early-stage Parkinson's disease (PD). You would receive either prasinezumab or a placebo (an inactive substance) through an IV (into your vein). The researchers want to see if prasinezumab can slow down the worsening of motor symptoms (movement problems) over at least 104 weeks, as measured by a special rating scale (MDS-UPDRS Part III). The study aims to enroll about 900 participants. To join, you should be between 50 and 85 years old, weigh between 88 and 242 pounds, and have a diagnosis of idiopathic PD. Your Parkinson's should be at an early stage (Hoehn and Yahr Stage 1 or 2) and you should be taking only one stable medication for your symptoms.

Study design

This is an interventional study comparing prasinezumab to a placebo. It plans to enroll about 900 participants.

What's involved

You would receive either prasinezumab or a placebo as an IV infusion according to a set schedule. The primary outcome is measured for at least 104 weeks.

Compensation

Not stated in the trial record.

Follow-up

Your motor progression will be measured for up to at least Week 104 after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.